An observational, longitudinal study analysing impact of erenumab on cerebral hemodynamics and endothelial function in migraine without aura and compared with healthy control
Latest Information Update: 04 Sep 2020
At a glance
- Drugs Erenumab (Primary)
- Indications Migraine without aura
- Focus Pharmacodynamics
- 04 Sep 2020 New trial record
- 31 Aug 2020 Results published in the Cephalalgia